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The role of the immune system in neuropsychiatric diseases, including autism spectrum disorder (ASD), has long been
hypothesized. This hypothesis has mainly been supported by family cohort studies and the immunological abnormalities found
in ASD patients, but had limited ﬁndings in genetic association testing. Two cross-disorder genetic association tests were
performed on the genome-wide data sets of ASD and six autoimmune disorders. In the polygenic score test, we examined
whether ASD risk alleles with low effect sizes work collectively in speciﬁc autoimmune disorders and show signiﬁcant
association statistics. In the genetic variation score test, we tested whether allele-speciﬁc associations between ASD and
autoimmune disorders can be found using nominally signiﬁcant single-nucleotide polymorphisms. In both tests, we found that
ASD is probabilistically linked to ankylosing spondylitis (AS) and multiple sclerosis (MS). Association coefﬁcients showed that
ASD and AS were positively associated,meaning that autism susceptibility allelesmay have a similar collectiveeffectin AS. The
association coefﬁcients were negative between ASD and MS. Signiﬁcant associations between ASD and two autoimmune
disorders wereidentiﬁed. Thisgeneticassociation supportsthe idea that speciﬁc immunologicalabnormalitiesmay underlie the
etiology of autism, at least in a number of cases.
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Introduction
Autism spectrum disorder (ASD) is a broad spectrum of early-
onset neuropsychiatric disorders characterized by severe
deﬁcitsinsocialinteractionandlanguage,andthepresenceof
repetitive and stereotyped behaviors and interests.
1 Twin
studies have demonstrated that ASD is largely genetic, with a
90% concordance between monozygotic twins, and heritable,
with a 5–10 times higher familial risk than in the general
population.
2,3 Genome-wide association studies (GWASs)
have discovered signiﬁcant genetic markers of single-nucleo-
tide polymorphisms (SNPs)
4–6 and de novo mutations of copy
number variations
7–10 that may cause ASD. However, the
molecular pathology of ASD is largely unclear owing to its
genetic heterogeneity and the fact that only a small proportion
of incidence is explained by known susceptibility loci.
11,12
Given this heterogeneity, it has been suggested that cross-
disease analysis between ASD and other disorders that share
common phenotypic symptoms or genetically susceptible loci
will shed light on our understanding of the molecular
mechanisms underlying ASD.
13
The role of the immune system in neuropsychiatric
diseases, including ASD, has long been hypothesized
14–16
and is mainly supported by family cohort studies and the
immunological abnormalities found in autistic patients. For
example, Atlado ´ttir et al.
17 reported that the risk of ASD
increases when a child’s mother has rheumatoid arthritis or
has a family history of type 1 diabetes. Other autoimmune
disorders for which epidemiological studies have shown
signiﬁcantassociationwithASD,includematernalpsoriasis,
18
maternal ulcerative colitis,
19 and autoimmune thyroid disease
(ATD).
20 In addition, various forms of immune dysregulation,
including elevated cytokine levels
21–23 and increased immu-
noglobulin and serum protein levels,
24–26 have been identiﬁed
in autistic children. However, few studies have reported
potential genetic components that account for associations
between ASD and autoimmune disorders. In fact, only three
alleles, two in the human leukocyte antigen (HLA-DR4,
27,28
DR13,
27 HLA-A2
29) and one in the major histocompatibility
complex (MHC) of chromosome 6 (the C4B null allele
30) have
a conﬁrmed association with ASD. With the advent of GWAS
and the availability of large amounts of genotype data from
both ASD and multiple autoimmune diseases, we now have
the ability to directly analyze genetic associations across
these diseases.
Materials and methods
Study samples and data quality control. We obtained
Illumina BeadChip 550K genotype data of 941 multiplex
families (Illumina Inc., San Diego, CA, USA) with autistic
children from the Autism Genetic Resource Exchange
(AGRE).
31 For the phenotype labeling, we followed the
classiﬁcation of the Autism Diagnostic Interview—Revised
32
included in the AGRE phenotype database, but excluded
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classiﬁcation did not agree. We examined each family’s data
to ﬁnd monozygotic twins, triplets, or quadruplets and elected
to include only one monozygotic sibling per family, ﬁltering 72
individuals from the data set. We also removed 92 individuals
who were annotated as ‘possible non-idiopathic autism’ in the
AGRE phenotype database. These cases include prematurity
of less than 35 weeks gestation (45 individuals), Fragile X
syndrome (12 individuals), known chromosomal abnormality
(10 individuals), and other diagnosed neurogenetic disorders
(10 individuals). We further applied a set of quality control
ﬁlters in order to identify a stringent subset of robust SNPs.
We excluded 32 individuals with genotyping rate o0.95 and
18510 SNPs with genotyping rate o0.95. We examined
Mendelian error per each family trio, and removed seven
individuals for Mendelian error 41 percent of all markers.
SNPs with a minor allele frequency o0.05 or with a Hardy–
Weinberg equilibrium exact test Po0.001 were excluded from
further analysis. After quality control, the ASD genomic data
consisted of 1397 affected trios and a total of 470025 SNPs.
We used the software package PLINK
34 to conduct the
transmission disequilibrium test (TDT) with all family trios
passing quality control without identifying subpopulation, as
the TDT is known to maintain the desired type 1 error rate in
the presence of population stratiﬁcation.
35
We obtained two groups of GWAS data from the Wellcome
Trust Case Control Consortium (WTCCC) as target disease
sets for measuring association with ASD. The smaller set
(WTCCC4) consisted of 1500 common controls and 1000
independent cases of ankylosing spondylitis (AS), auto-
immune thyroid disease, multiple sclerosis (MS), and breast
cancer. It had 14436 non-synonymous SNPs plus 897 SNPs
in the major histocompatibility complex region, and was
genotyped using the Illumina Inﬁnium 15K array. The larger
set (WTCCC7) in the Affymetrix GeneChip 500K array
(Affymetrix Inc., Santa Clara, CA, USA) consisted of 3000
shared controls and 2000 independent cases in seven
diseases, including bipolar disorder, coronary artery disease,
Crohn’s disease, hypertension, rheumatoid arthritis, type 1
diabetes and type 2 diabetes. Shared control samples came
from two sources: for the smaller set (WTCCC4), control
samples were taken from the 1958 British Birth Cohort (58C)
and for the larger set (WTCCC7), 1500 control samples were
taken from 58C. The remaining 1500 samples were taken
from blood donors recruited by the three UK Blood Services
(UKBS).
36,37 Although the ages of the former are known and
past the typical age of onset for the autoimmune conditions
studied, the individual age information of the UKBS group is
not known. The potential variation in ages from this control
group could introduce minor classiﬁcation bias, as some of
individuals may (or may have) develop the autoimmune
disorder in the future, as discussed in the main WTCCC7
article.
37 However, the prevalence of these autoimmune
disorders is relatively rare, with a combined prevalence of
rate of up to 8 percent.
38 Therefore, although we do not have
detailed age information for the UKBS samples, we assume
that misclassiﬁcation due to age of onset would be rare and
unlikely to bias our results. We followed the quality control
steps described in Burton et al.,
36,37 and further removed
SNPs with minor allele frequency o0.05 or Hardy–Weinberg
equilibrium exact test Po0.001. After quality control steps,
there were 12700 SNPs remaining in the WTCCC4 set, and
469557SNPswereretainedforfurtheranalysisintheWTCCC7
set. Across all SNPs passing quality control, we used case–
control association analysis with the software package PLINK.
As these data were genotyped using different platforms, we
cross-referenced SNP ids and strand information as follows.
First we converted all custom, non-reference SNP ids into
corresponding reference SNP ids by querying the UCSC
Genome Browser (http://www.genome.uscs.edu; version May
2004/NCBI genome build 35). Thenwe examined all reference
SNP ids to conﬁrm that they are up-to-date by querying NCBI
dbSNP (build 132) and removed six SNPs that had multiple
identiﬁers. Next, we checked all the allelic and chromosomal
position information of each data set with the HapMap
genotype data (CEU founders, release 23), reconﬁguring the
strands when alleles did not match. Mapping SNPs into the
corresponding gene regions was done by querying NCBI
dbSNP (build 132). The number of intersection SNPs between
ASD and WTCCC4 set was 5318, and the number of
intersectionSNPsbetweenASDandWTCCC7setwas73331.
Polygenic score analysis. To identify genomic asso-
ciations between diseases, we used two separate and
complementary approaches, as illustrated in Figure 1. The
ﬁrst, the polygenic score (PS) test
39 measured the collective
effect of disease-associated SNPs from one disease on a
collection of SNPs from another. The test was designed to
identify associations between complex multigenic diseases
that manifest through a combination of multiple variants of
small individual effect. We used the PS test here to
determine if collections of variants from cases with ASD
appear to correlate with groups of variants from individuals
with autoimmune disorders. First, we labeled a GWAS data
set from one disease as the ‘source’ data set and another
GWAS from a different disease as the ‘target’. From the
source data set we selected groups of autosomal SNPs that
corresponded to a range of nominal signiﬁcance thresholds
(PT) as source alleles, and recorded the minor allele and
odds ratio information of those selected SNPs. Then, for
each individual in the target data set, we calculated the PS by
computing the average number of source alleles that the
individual had, weighted by the logarithm-of-the-odds-ratio
(log (odds-ratio)) from the source data set. This polygenic
score can be considered to be a measure of probabilistic
similarity for those SNPs in the source disease data set and
each individual in the target data set. As such, if the source
and target diseases were highly similar in allelic composition,
the cases would yield consistently higher scores than the
controls. If there were multiple target diseases, ones that
were more closely related to the source disease would yield a
higher average PS, as demonstrated in International
Schizophrenia Consortium.
39 To provide this context, we
ran logistic regression analysis with the PS to predict the
classiﬁcation of the target disease. Then, we estimated the
variance explained in the target disease data by the PS using
the Nagelkerke’s pseudo R-square
40 from a model with the
PS and covariates, versus that from a model without the
score. We took the total number of alleles used to calculate
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individuals in the WTCCC data sets as covariates.
Genetic variation score analysis. The second metric we
used to compare ASD to autoimmune disorders was the
genetic variance score (GVS).
39 With GVS, a combined
score of the odds-ratio and P-value was deﬁned for each
disease data set and every SNP belonging to that set.
Speciﬁcally, for each disease data set d and a SNP sAd,a
GVS of [d, s] was deﬁned as sign (log(odds-ratio [d, s])) *
( log10(P-value [d, s])). Given that the odds-ratio was
calculated with respect to the minor allele of the SNP and
that the odds-ratio was greater than 1 when the minor allele
was more likely to occur in the case group, the sign (log
(odds-ratio)) was positive when the minor allele was the risk
allele, and negative when the major allele was the risk allele.
When the GVS scores of a SNP in two diseases had different
signs, we assumed that the allele was protective in one
disease and deleterious in the other. As an extension of this
allele-speciﬁc comparison, we computed the Pearson pair-
wise correlation between the GVS data of two diseases. This
correlation analysis enabled us to determine whether large
numbers of SNPs have similar effects in two different
diseases, that is, a high positive correlation coefﬁcient
indicated similar effects, whereas a strong negative
coefﬁcient indicated opposing effects of the risk alleles.
Although both of these two approaches were based on
individual SNP association and framed in terms of odds-ratios
and P-values, they provided two complementary assess-
ments of the association between the genotypes of two
differentdiseases.ThePStestassignedascoreperindividual
in the target disease set and assumed that many weakly
associated SNPs with marginal odds-ratios may work
collectively, such that they have stronger association test
statistics than loci drawn from the null distribution. The GVS
and its Pearson correlation as a similarity measure examined
whether there were SNPs with strong signiﬁcance in both
disease sets, as GVS compared the pair-wise, allele-speciﬁc
signiﬁcance of each SNP.
Results
PS analysis. We examined whether groups of ASD-
associated SNPs can collectively account for genomic
variation in another disease, even when each individual
SNP may not have a very strong effect. From this source
sample, we selected sets of marginally associated alleles at
ﬁve different P-value thresholds (PT o0.01, 0.05, 0.1, 0.25
and 0.5). After calculating PS per each individual in each
target autoimmune data set, we performed a logistic regres-
sion analysis using the PS as a predictor of target disease
classiﬁcation, and estimated the variance in the target
sample explained by the PS using Nagelkerke’s pseudo R
2.
Table 1 summarizes this R
2 measure with P-value thresholds
for each group of source alleles and target diseases. Source
alleles from ASD data showed a signiﬁcant enrichment in AS
cases (P¼2.22 10
 16 at PTo0.5), explaining about two
percent of variance. In addition, the effect of source alleles
became larger when the P-value threshold PT was increased,
supporting our hypothesis that alleles with little individual
effect in one disease may work collectively in other diseases.
In MS, source alleles showed a similar pattern of increasing
R
2 with increasing PT thresholds, explaining about one
percent of variance (P¼5.16 10
 5 at PT o 0.5). In contrast
to AS, however, the coefﬁcients of the PS in MS were all
negative and the average mean score was higher in controls
(data not shown), suggesting that ASD risk alleles have
opposite overall effects in these two diseases. In other
WTCCC target diseases, the variance explained by ASD
source alleles was either too small (R
2 o 0.01), or was not
signiﬁcant (P40.05) over all P-value thresholds.
Genetic variation score analysis. Next, we examined
whether allele-speciﬁc associations can be found among
Figure 1 Analysis steps in the polygenic score approach (a) and genetic variation score approach (b). In both approaches, P-values and odd-ratios were calculated from
transmissiondisequilibriumtest(ASDdata)orcase/controlassociationtest(WTCCCdata)afterqualitycontrolsteps.(a)FromtheASDdatasetandagivenPvaluethreshold
PT, a set of SNPs with PoPT were selected as ‘source alleles’. Then for each target disease data set, the polygenic score was calculated for each individual. We conducted
logisticregressionanalysiswiththepolygenicscoresinorderto examinewhethersourceallelesfromASDdatacouldexplainvariancesinthetargetdiseasedatasets.(b)For
each ASD and autoimmune data set, the genetic variation score was calculated for each SNP. We used Pearson’s pair-wise correlation to compare the collective effect of
SNPs in two diseases.
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approach. As we examined the collective effect of marginally
signiﬁcant SNPs and found enrichment in two autoimmune
diseases in the PS approach, here we focused our analysis on
SNPs with at least nominally signiﬁcant P values (P o 0.05).
Multiple hypothesis correction was not applied to the P values
when calculating GVS because we examined associations of
disease pairs by correlation coefﬁcients, which would not
change after multiple hypothesis correction. Table 2 shows
the Pearson correlation coefﬁcients for all disease pairs within
ASD and the WTCCC data sets, calculated with GVS.
Consistent with the results from the PS analysis above, the
ASD data exhibited signiﬁcant positive association with AS
(coefﬁcient 0.4032) and signiﬁcant negative association with
MS (coefﬁcient  0.3092). AS and MS were also strongly
negatively associated with one another (coefﬁcient  0.3092).
Interestingly, the coefﬁcient of association between ASD and
AS was higher than any of the autoimmune disease pairs,
while the strength of the association between ASD and
MS was comparable to that of strengths of association
between any pair of autoimmune disorders. Autoimmune
thyroid disease was slightly positively correlated with ASD
(coefﬁcient 0.2012), whereas all other autoimmune diseases
(MS, Crohn’s disease and rheumatoid arthritis) showed little
association with ASD in their proﬁles. Table 3 summarizes the
nominally signiﬁcant SNPs in both ASD and the autoimmune
diseases, including AS and MS. Many of these SNPs fell within
already known ASD risk genes (for example, rs2034648—
AGAP1) or mental disorder susceptibility genes (for example,
rs11643718–SLC12A3 and rs3132468–MICB). Another group
of SNPs fell within the protein coding regions of several known
autoimmune risk genes (for example, rs3130559–PSORS1C1,
rs3129943–C6orf10 and rs3130542–HLA-C). However, none
of these have been reported previously as ASD susceptibility
genes.
Discussion
GiventhatthemagnitudeoftheassociationbetweenASDand
the two autoimmune diseases, AS and MS, was either greater
than or on par with the strength of association between what
are considered now to be genetically similar autoimmune
diseases, coupled with the lack of any other association of the
same signiﬁcance between ASD and the remaining auto-
immunedisordersexamined,ourresultsclearlydemonstrated
that there are true genomic links between ASD and the two
autoimmune diseases, links that likely can inform our under-
standing of the genetics and treatments of ASD. However,
further study and veriﬁcation is required to characterize and
explain these particular genomic associations. An interesting,
albeit anecdotal, similarity between ASD and AS is that they
both have an appreciable male bias. AS has a male-to-female
ratioofapproximately2.5:1
42thatisofthesamemagnitudeas
the male bias of ASD’s 4:1
43 while other autoimmune
Table 1 Logistic regression analysis results of ASD and WTCCC disease data
Source: ASD Target sample pseudo-R
2   100 (P value)
PT 0.01 0.05 0.1 0.25 0.5
WTCCC 4
AS 0.21 (1.44e–07) 0.39 (2.14e–09) 1.04 (5.27e–11) 1.59 (1.04e–13) 2.28 (2.22e–16)
ATD 0.01 (1.99e–04) 0.17 (9.51e–05) 0.35 (1.26e–06) 0.31 (6.64e–08) 0.33 (1.72e–08)
BC 0.00 (2.29e–11) 0.10 (9.09e–11) 0.01 (6.75e–11) 0.03 (8.88e–15) 0.02 (1.11e–16)
MS 0.07 (2.79e–01) 0.17 (8.49e–01) 0.76 (8.81e–04) 0.90 (7.56e–05) 1.05 (5.16e–05)
WTCCC 7
BD 0.33 (1.54e–02) 0.38 (8.52e–03) 0.08 (3.70e–01) 0.25 (4.49e–02) 0.16 (1.42e–01)
CAD 0.01 (9.27e–01) 0.38 (8.36e–03) 0.12 (2.17e–01) 0.04 (6.12e–01) 0.06 (3.90e–01)
CD 0.11 (2.64e–01) 0.17 (1.73e–01) 0.22 (7.33e–02) 0.25 (2.46e–01) 0.20 (5.01e–02)
HT 0.03 (7.10e–01) 0.11 (2.46e–01) 0.02 (7.87e–01) 0.09 (8.29e–01) 0.11 (8.68e–01)
RA 0.05 (5.69e–01) 0.15 (4.15e–02) 0.25 (1.24e–01) 0.17 (8.83e–02) 0.22 (5.16e–02)
T1D 0.11 (2.34e–01) 0.16 (1.29e–01) 0.21 (6.99e–02) 0.38 (7.32e–03) 0.29 (1.58e–02)
T2D 0.04 (6.34e–01) 0.18 (1.01e–01) 0.04 (5.75e–01) 0.05 (7.22e–01) 0.03 (8.64e–01)
Abbreviations: AS, ankylosing spondylitis; ASD, autism spectrum disorder; ATD, autoimmune thyroid disease; BC, breast cancer; BD, bipolar disorder; CAD,
coronary artery disease; CD, Crohn’s disease; HT, hypertension; MS, multiple sclerosis; PT, P-value threshold; RA, rheumatoid arthritis; T1D, type 1 diabetes; T2D,
type 2 Diabetes; WTCCC, Wellcome trust case control consortium.
Table 2 Pairwise GVS correlation coefﬁcients between ASD and WTCCC data sets
AS ATD BC MS
GVS
1 (#SNPs) 0.4032 (28) 0.2012 (34) 0.0254 (16)  0.3092 (36)
BD CAD CD HT RA T1D T2D
GVS
1 (#SNPs)  0.0895 (276)  0.0868 (267)  0.0125 (288)  0.0360 (250)  0.0588 (258) 0.0127 (240)  0.0546 (261)
Abbreviations: AS, ankylosing spondylitis; ASD, autism spectrum disorder; ATD, autoimmune thyroid disease; BC, breast cancer; BD, bipolar disorder; CAD,
coronary artery disease; CD, Crohn’s disease; GVS, genetic variation score; HT, hypertension; MS, multiple sclerosis; RA, rheumatoid arthritis; SNPs, single-
nucleotide polymorphisms; T1D, type 1 diabetes; T2D, type 2 diabetes; WTCCC, Wellcome trust case control consortium. Number of the common SNPs in both
diseases with Po0.05 is shown in paranthesis.
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42,43 generally show
higher susceptibility in females. Also of interest to the
observed genomic similarities between ASD and AS is anti-
TNF (tumor necrosis factor) alpha treatment therapy. Anti-
TNF agents are among the most efﬁcacious options for
treatment of AS,
46,47 and, although not well studied to date,
ASD cases have been shown to have increased expression
levels of TNF-alpha and IL-6,
48 and separate cases have
received anti-TNF therapy.
49 Interestingly, anti-TNF agents
tend to cause demyelination as an adverse side effect,
50 a
symptom that is typical in MS.
Toruleoutthepossibilitythattheratioofmalestofemalesin
our original data sets biased our ﬁndings, we constructed sex-
balanced and gender-speciﬁc data sets and recomputed the
polygenic scores. The direction and relative strength of
correlation with AS and MS remained unchanged, indicating
that our results are not unduly inﬂuenced by the different
numbers of male and female cases in the data sets. To rule
out the possibility that differences in population heterogeneity
and ethnic background between the ASD and the autoimmu-
nity data collections biased the ﬁndings, we tested for
association using only ASD individuals of European ancestry
to match the ancestry of the individuals included within the
autoimmune data sets. With a reduced number of 1019
affected trios from the ASD data set, we conducted TDT
analysis and PS testing and found results consistent with
those found using the complete ASD data set, a positive
association with AS and negative association with MS and no
othersigniﬁcantassociationsbetweenASDandtheremaining
autoimmune disorders studied. These results suggest that
differences in mixed ancestry between the two data sets did
not inﬂuence the associations discovered. However, this lack
of bias from mixed ancestry does not preclude the possibility
that geographical differences (our ASD collection was from
theUnitedStates,whileautoimmune collectionswere fromthe
United Kingdom), and consequent differences in environmen-
tal exposure, could inﬂuence risk for disease differently as
has been shown in the MS cases.
51 However, differences
in exposure related to geography are more likely to cause
underestimates of association rather than overestimates and
are thus unlikely to alter the results shown here. An additional
potential bias could arise from the age of onset of autoimmune
conditions. For example, MS tends to manifest in women
during childbearing ages. Our ASD sample contains mothers
who have, by deﬁnition, passed childbearing age, butbecause
the mothers served as controls in the association testing, the
observed negative association between ASD and MS sug-
gests that mothers in the ASD set had a higher loading of
MS-relatedalleles,notalowerloading.Underthisassumption,
itisunlikelythatdifferencesinagesofthesampledpopulations
biased the signiﬁcance or directionality of the association
identiﬁed. Nevertheless, further studies with more equivalent
samples across parameters, including age, ancestry and
geography would be valuable to verify our ﬁndings.
In conclusion, we found signiﬁcant, allele-speciﬁc genomic
associations between ASD and two autoimmune diseases,
AS and MS, which were supported using two complementary
analytical strategies. The ﬁrst, a PS approach, revealed that a
collection of relatively weakly associated ASD susceptibility
markers could still explain a signiﬁcant percentage of the
variation in both AS and MS cases. Coefﬁcients from logistic
regression analysis with the polygenic scores showed that
the collective, allele-speciﬁc role of SNPs in ASD and AS
was similar, whereas the roles of the alleles explaining the
similarity between ASD and MS were of opposite effect,
conferring risk in one and protection from onset in the other.
The second, a genetic variation score approach, found the
same results of allele-speciﬁc association between ASD and
AS and ASD and MS with comparable or higher strength of
associationthanthatfoundbetweenanyautoimmunedisease
pair. Together these results suggest that common genetic
mechanisms exist between ASD and AS and that opposing
genetic mechanisms exist between ASD and MS. Both
approaches pinpoint sets of SNPs that comprise the
signiﬁcant associations seen in our study and that may be of
value as targets for further experiments aimed at under-
standing the genetic ties between ASD and autoimmune
diseases.
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